Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel.

@article{Rixe1996OxaliplatinTC,
  title={Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel.},
  author={O Rixe and Waldo Ortuzar and Montserrat {\'A}lvarez and Reno Parker and Eddie B. Reed and Kenneth Paull and Tito Fojo},
  journal={Biochemical pharmacology},
  year={1996},
  volume={52 12},
  pages={1855-65}
}
The present study was designed to explore the activity of platinum compounds in cisplatin-resistant cell lines, the unselected cell lines of the National Cancer Institute's Anticancer Drug Screen, and the potential for use in combination. The activities of four platinum compounds in cisplatin-resistant KB and A2780 cells were investigated. The cells were highly resistant to cisplatin and cross-resistant to carboplatin, but less than one-tenth as resistant to oxaliplatin and tetraplatin… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 171 extracted citations

Oxaliplatin-induced damage of cellular DNA.

Molecular pharmacology • 2000
View 4 Excerpts
Highly Influenced

Oxaliplatin: a review of preclinical and clinical studies.

Annals of oncology : official journal of the European Society for Medical Oncology • 1998
View 8 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…